BR112012005343A2 - sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer - Google Patents
sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncerInfo
- Publication number
- BR112012005343A2 BR112012005343A2 BR112012005343A BR112012005343A BR112012005343A2 BR 112012005343 A2 BR112012005343 A2 BR 112012005343A2 BR 112012005343 A BR112012005343 A BR 112012005343A BR 112012005343 A BR112012005343 A BR 112012005343A BR 112012005343 A2 BR112012005343 A2 BR 112012005343A2
- Authority
- BR
- Brazil
- Prior art keywords
- sulfonamides
- bcl
- cancer treatment
- family protein
- protein inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 title 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24125109P | 2009-09-10 | 2009-09-10 | |
| PCT/EP2010/063169 WO2011029842A1 (en) | 2009-09-10 | 2010-09-08 | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012005343A2 true BR112012005343A2 (pt) | 2016-03-22 |
Family
ID=43016684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012005343A BR112012005343A2 (pt) | 2009-09-10 | 2010-09-08 | sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8809352B2 (enExample) |
| EP (1) | EP2475661B1 (enExample) |
| JP (1) | JP2013504536A (enExample) |
| KR (1) | KR20120078715A (enExample) |
| CN (1) | CN102498111A (enExample) |
| AU (1) | AU2010294292B2 (enExample) |
| BR (1) | BR112012005343A2 (enExample) |
| CA (1) | CA2772989A1 (enExample) |
| EA (1) | EA020586B1 (enExample) |
| ES (1) | ES2443845T3 (enExample) |
| MX (1) | MX2012003007A (enExample) |
| WO (1) | WO2011029842A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012209295B2 (en) * | 2011-01-25 | 2016-06-30 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| AU2012355623A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| LT6064B (lt) | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai |
| MD4635C1 (ro) | 2013-10-14 | 2020-01-31 | Eisai R&D Management Co., Ltd. | Compuşi de chinolină substituiţi selectiv |
| WO2015057655A1 (en) | 2013-10-14 | 2015-04-23 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| CN108349924A (zh) * | 2015-08-12 | 2018-07-31 | 纪念斯隆凯特林癌症中心 | 苯磺酰氨基-苯并呋喃衍生物及其用途 |
| JP2019501225A (ja) * | 2016-01-11 | 2019-01-17 | メリマック ファーマシューティカルズ インコーポレーティッド | Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害 |
| WO2017123588A1 (en) | 2016-01-11 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Inhibiting ataxia telangiectasia and rad3-related protein (atr) |
| FI3788042T3 (fi) | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| KR20210145787A (ko) | 2019-04-02 | 2021-12-02 | 알리고스 테라퓨틱스 인코포레이티드 | Prmt5를 표적으로 하는 화합물 |
| TW202200574A (zh) | 2020-04-15 | 2022-01-01 | 英屬開曼群島商百濟神州有限公司 | Bcl-2抑制劑 |
| EP4538273A1 (en) * | 2022-06-10 | 2025-04-16 | Hitgen Inc. | Compound and use thereof in preparation of bcl-xl inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1487811B1 (en) * | 2002-03-21 | 2007-09-05 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
| US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| ZA200702257B (en) * | 2004-08-20 | 2009-06-24 | Univ Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
| WO2008061208A2 (en) * | 2006-11-15 | 2008-05-22 | Genentech, Inc. | Arylsulfonamide compounds |
| FR2912145B1 (fr) * | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2010
- 2010-09-08 MX MX2012003007A patent/MX2012003007A/es active IP Right Grant
- 2010-09-08 ES ES10750124.9T patent/ES2443845T3/es active Active
- 2010-09-08 US US13/394,525 patent/US8809352B2/en not_active Expired - Fee Related
- 2010-09-08 BR BR112012005343A patent/BR112012005343A2/pt not_active IP Right Cessation
- 2010-09-08 CN CN2010800396704A patent/CN102498111A/zh active Pending
- 2010-09-08 KR KR1020127009091A patent/KR20120078715A/ko not_active Withdrawn
- 2010-09-08 EA EA201200472A patent/EA020586B1/ru not_active IP Right Cessation
- 2010-09-08 AU AU2010294292A patent/AU2010294292B2/en not_active Ceased
- 2010-09-08 CA CA2772989A patent/CA2772989A1/en not_active Abandoned
- 2010-09-08 WO PCT/EP2010/063169 patent/WO2011029842A1/en not_active Ceased
- 2010-09-08 JP JP2012528347A patent/JP2013504536A/ja active Pending
- 2010-09-08 EP EP10750124.9A patent/EP2475661B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| ES2443845T3 (es) | 2014-02-20 |
| EA201200472A1 (ru) | 2012-10-30 |
| AU2010294292A1 (en) | 2012-03-01 |
| EP2475661B1 (en) | 2013-10-23 |
| JP2013504536A (ja) | 2013-02-07 |
| WO2011029842A1 (en) | 2011-03-17 |
| US8809352B2 (en) | 2014-08-19 |
| KR20120078715A (ko) | 2012-07-10 |
| AU2010294292B2 (en) | 2013-07-18 |
| US20120165298A1 (en) | 2012-06-28 |
| EA020586B1 (ru) | 2014-12-30 |
| MX2012003007A (es) | 2012-04-11 |
| CN102498111A (zh) | 2012-06-13 |
| CA2772989A1 (en) | 2011-03-17 |
| EP2475661A1 (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012005343A2 (pt) | sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer | |
| BRPI1008566A8 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| PT3483143T (pt) | Derivados da piperidinona como inibidores da mdm2 para o tratamento do cancro | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
| BRPI1015215A2 (pt) | porções de ligação alvo armadas com amatoxina para o tratamento de câncer | |
| BRPI1008564A2 (pt) | métodos e composições para o dignóstico e tratamento de câncer | |
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| BRPI1010874A8 (pt) | composição para o tratamento de câncer de próstata | |
| BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
| CO6930321A2 (es) | Curación de tejidos | |
| BR112013008738A2 (pt) | processos para purificação de proteínas | |
| PT2523661T (pt) | Inibidores de nkcc para o tratamento de autismo | |
| BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| PT2632452T (pt) | Compostos e composições para o tratamento do cancro | |
| EP2627333A4 (en) | Combination treatment of cancer | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BR112015006512A2 (pt) | composição para tratar tecidos biológicos danificados | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| PT2552963E (pt) | Anticorpos anti cxcr4 humanizados para o tratamento de cancro | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |